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Background: Empiric triple treatments for Helicobacter pylori (H. pylori) are increasingly unsuccessful. We evaluated
factors associated with failure of these treatments in the central region of Portugal.
Methods: This single-center, prospective study included 154 patients with positive 13C-urea breath test (UBT).
Patients with no previous H. pylori treatments (Group A, n = 103) received pantoprazole 40 mg 2×/day, amoxicillin
1000 mg 12/12 h and clarithromycin (CLARI) 500 mg 12/12 h, for 14 days. Patients with previous failed treatments
(Group B, n = 51) and no history of levofloxacin (LVX) consumption were prescribed pantoprazole 40 mg 2×/day,
amoxicillin 1000 mg 12/12 h and LVX 250 mg 12/12 h, for 10 days. H. pylori eradication was assessed by UBT
6–10 weeks after treatment. Compliance and adverse events were assessed by verbal and written questionnaires.
Risk factors for eradication failure were determined by multivariate analysis.
Results: Intention-to-treat and per-protocol eradication rates were Group A: 68.9% (95% CI: 59.4–77.1%) and 68.8%
(95% CI: 58.9–77.2%); Group B: 52.9% (95% CI: 39.5–66%) and 55.1% (95% CI: 41.3–68.2%), with 43.7% of Group A
and 31.4% of Group B reporting adverse events. Main risk factors for failure were H. pylori resistance to CLARI and
LVX in Groups A and B, respectively. Another independent risk factor in Group A was history of frequent infections
(OR = 4.24; 95% CI 1.04–17.24). For patients with no H. pylori resistance to CLARI, a history of frequent infections
(OR = 4.76; 95% CI 1.24–18.27) and active tobacco consumption (OR = 5.25; 95% CI 1.22–22.69) were also associated
with eradication failure.
Conclusions: Empiric first and second-line triple treatments have unacceptable eradication rates in the central
region of Portugal and cannot be used, according to Maastricht recommendations. Even for cases with no H. pylori
resistance to the used antibiotics, results were unacceptable and, at least for CLARI, are influenced by history of
frequent infections and tobacco consumption.
Keywords: Clarithromycin, Compliance, Helicobacter pylori, Levofloxacin, Treatment failureBackground
Approximately 50% of the world population is infected
by Helicobacter pylori (H. pylori). This bacterium is
responsible for multiple gastric diseases, including gas-
troduodenal ulcer, gastric adenocarcinoma and mucosa-
associated lymphoid tissue lymphoma [1-3]. After almost
thirty years of treating H. pylori, the ideal regimen has* Correspondence: nunoperesalmeida@gmail.com
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unless otherwise stated.not been found. Some consensus conferences have rec-
ommended treatments with cure rates of ≥80% on an
intention-to-treat (ITT) basis [4]. More recently, regimens
of at least 90–95% efficacy, and preferably 95–100%, have
been suggested as the standard of care [5].
Although meta-analyses have reported a decreased ef-
fectiveness for triple regimens containing clarithromycin
(CLARI), the so-called “legacy triple therapy” is still widely
used in several countries; the last Maastricht consensus
maintained it as a first-line treatment under certain condi-
tions [2,5,6]. The main reason for failure of this regimen isl. This is an Open Access article distributed under the terms of the Creative
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H. pylori resistance to this drug increased from 9.9% to
17.5% in one decade [8,9]. In fact, H. pylori infections re-
fractory to first treatment attempts are becoming more
frequent with expanding use of antibiotics for multiple in-
fections and the rising number of patients who undergo
H. pylori treatment.
After failure of a therapy containing proton pump in-
hibitor (PPI) and CLARI, either bismuth-based quadru-
ple therapy or PPI–levofloxacin (LVX) triple therapy is
recommended by the most recent Maastricht consensus
(2012) [2]. Multiple studies and meta-analysis have shown
LVX to be a valid alternative to standard antimicrobial
agents in first- and second-line regimens [10-12]. It is
active even in H. pylori strains resistant to CLARI and
metronidazole. Eradication rates of patients who harbor
these doubly resistant strains are reportedly 92% if the iso-
lates are sensitive to LVX [13]. Levofloxacin-based therapy
can be used as second-line treatment in countries with
low prevalence of LVX-resistant strains, but should prob-
ably be used only as third-line therapy if resistance to this
fluoroquinolone is higher than 15% [14].
The H. pylori prevalence rate in Portuguese adults is
84.2% [15]. Although the aforementioned empirical triple-
therapies are regularly used in the central region of
Portugal, to our knowledge, there is no information
about the efficacy of these treatments.
This study evaluated eradication rates of a 14-day
triple therapy with PPI, amoxicillin and CLARI as em-
piric first-line therapy and a 10-day triple treatment with
PPI, amoxicillin and LVX as a rescue therapy. As sec-
ondary aim, we intended to identify clinical and bacterial
factors associated with treatment failure.
Methods
Patients
In this single-center study, patients with dyspepsia, iron-
deficient anemia, need for chronic therapy with PPI and/
or first-degree relatives with gastric carcinoma were pro-
spectively considered for inclusion. Each had a recent
positive 13C-urea breath test (UBT) and indication for
upper endoscopy. Exclusion criteria were: age <18 years;
pregnancy; lactating and/or fertile women who were not
using safe contraceptive methods; history of allergy/
hypersensitivity to any antibiotic or PPI; previous gastric
malignancy and/or gastric surgery; current use of anti-
coagulants; marked thrombocytopenia; systemic severe
disease (hepatic, cardio-respiratory or renal disease; un-
controlled diabetes; active malignant diseases, coagulop-
athies); use of antibiotics in the last 4 weeks; use of PPI
in the last 2 weeks; intolerance/refusal to undergo upper
endoscopy; previous H. pylori eradication treatments in-
cluding fluoroquinolones or known use of this antibiotic
for other infections.They were divided in two groups: Group A—patients
who had never received eradication treatments (n = 103;
73 female; mean age: 41.6 ± 12.9 years); Group B—
patients who failed ≥1 eradication attempts that did
not include LVX (n = 51; 39 female; mean age: 45.2 ±
13.9 years) and had no documented history of treat-
ment with fluoroquinolones.
Empiric triple treatments and efficacy assessment
After undergoing upper endoscopies, patients in Group
A were immediately prescribed pantoprazole 40 mg 2×/
day, amoxicillin 1000 mg 12/12 h and CLARI 500 mg
12/12 h, for 14 days. Patients in Group B were pre-
scribed pantoprazole 40 mg 2×/day, amoxicillin 1000 mg
12/12 h, and LVX 250 mg 12/12 h, for 10 days. We pro-
vided detailed explanation of the therapies and potential
secondary effects to patients and their families, who
were given diaries to record all administrations, side ef-
fects and symptoms during therapy. Patients were phoned
immediately after treatment to register compliance and
any potential symptoms or side effects. They underwent
UBT 6–10 weeks after treatment to assess H. pylori sta-
tus. At this time, compliance was confirmed by count-
ing tablets returned by each patient. Treatment was
considered complete if all medication was taken. Poor
compliance was assumed if <80% of the prescribed drugs
were taken.
Patients also returned the diaries they maintained dur-
ing treatment and were asked to assess tolerability and
efficacy of treatment in resolving symptoms by visual
scales from 0 to 10 (0: not tolerable at all, 10: excellent
tolerability; and 0: not efficacious, 10: fully efficacious,
respectively). Adverse events were scored as mild, mod-
erate or severe by their effect on daily activities (daily ac-
tivities not limited, limited to some extent, or not
possible at all, respectively) and need to discontinue
treatment. The scoring system was based on that pro-
posed by de Boer et al., with minor modifications [16].
During the study, patients could directly telephone an
investigator to resolve any doubts or problems that
occurred. Patients were allowed no antibiotics or antise-
cretory drugs 4 and 2 weeks, respectively, before their
UBTs, which were considered positive if δ above baseline
was ≥4‰.
Microbiological studies
As this was a research protocol and patients each had
indication for upper endoscopy, we took biopsies for
H. pylori culture, susceptibility testing and genotyping.
Minimum inhibitory concentrations (MIC) for amoxi-
cillin, CLARI and LVX, and point mutations in gene 23S
rRNA and in the quinolones resistance-determining re-
gion of the gyrA gene were determined by a previously
published protocol [17]. The cagA and vacA genotypes
Table 1 Patients’ demographic and clinical characteristics
Group A Group B
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mers selected from previously published works [18,19].n = 103 n = 51
Mean age (years) 41.6 ± 12.9 45.2 ± 13.9
(range 19–77) (range 18–85)
Sex
- Male 30 (29.1%) 12 (23.5%)Stopping rules
Efficacy assessment was performed in each group for
every 50 included patients. Inclusion was halted if this
preliminary analysis revealed eradication rates <80%.- Female 73 (70.9%) 39 (76.5%)
Ethnic background
- European 99 (96.1%) 50 (98%)
- African 4 (3.9%) 1 (2%)
Education level
- Level 1 30 (29.1%) 19 (37.3%)
- Level 2 73 (70.9%) 32 (62.8%)
Residence
- Rural 55 (53.4%) 30 (58.8%)
- Urban 48 (46.6%) 21 (31.2%)
Indication(s) for H. pylori
eradication
- Non-ulcer dyspepsia 63 (61.2%) 34 (66.7%)
- Iron-deficient anemia 25 (24.3%) 7 (13.7%)
- GERD/Chronic therapy with PPI 24 (23.3%) 17 (33.3%)
- First-degree relatives with
gastric cancer
14 (13.6%) 7 (13.7%)
- Peptic ulcer 9 (8.7%) 4 (7.8%)
BMI (Kg/m2) 24.6 ± 4.2 25 ± 4
(range 17.1–37.8) (range 17.1–33.8)
Alcohol consumption 21 (20.4%) 10 (19.6%)
Smoking 13 (12.6%) 11 (21.6%)Statistics
Categorical variables are shown with their relative and
absolute values; quantitative variables are expressed as
mean ± standard deviation or median + range. The H.
pylori eradication success was analyzed on both an ITT
basis (including all eligible enrolled patients, regardless
of compliance with study protocol; patients with unavail-
able data were assumed to be unsuccessfully treated)
and “per protocol” (PP) (including only patients with
good compliance and whose data was all evaluable at
end of treatment).
Univariate analyses with Student’s t test, Mann–Whitney
and Fisher’s exact test were used to evaluate associations
between treatment effectiveness and age, sex, ethnicity,
symptoms/indication for H. pylori treatment, body mass
index (BMI), location of residence, education level, olive
oil, alcohol and tobacco consumption, frequent infections,
use of antibiotics in the last 12 months, family history of
gastric pathology, H. pylori genotype, adverse events dur-
ing treatment and compliance. Significant variables were
subsequently included in a binomial logistic regression
that assumed H. pylori eradication as the dependent vari-
able. We used the statistical software package SPSS 20.0
(IBM Corp., Armonk, NY, USA).Olive oil consumption ≥1 dl/week 53 (51.5%) 27 (52.9%)
History of frequent infections 20 (19.4%) 13 (25.5%)
Antibiotic consumption in the
last 12 months
28 (27.2%) 40 (78.4%)
Family history of gastric diseases 49 (47.6%) 29 (56.9%)
BMI: body mass index; GERD: gastroesophageal reflux disease; PPI: proton
pump inhibitors; Level 1: no education or primary school; Level 2: high-school
or university grade.Ethics
The study was approved by the ethical committee of our
hospital and the Faculty of Medicine, and performed in
accordance with the Declaration of Helsinki, the Inter-
national Conference on Harmonisation of Good Clinical
Practice Guidelines, and applicable local laws and re-
gulations. Signed informed consent was obtained from
each patient.Results
Demographic variables
During the 4-year period, we included 154 patients
(Group A: n = 103; Group B: n = 51; Table 1). Group B pa-
tients received a median of one eradication (range: 1 to 5)
before inclusion with the following drugs: amoxicillin:
100%; CLARI: 92.2%; nitroimidazoles: 29.4%. The most
common regimen was triple therapy with PPI, amoxicillin
and CLARI, followed by PPI, CLARI and nitroimidazoles,
and by PPI, amoxicillin and nitroimidazoles.Compliance, tolerability/adverse events and follow-up
losses
Of the 103 patients in Group A, 25 (24.3%) failed to take
at least one pill during treatment but only 7 (6.8%) were
noncompliant; and 45 Group A patients (43.7%) experi-
enced adverse events (mild: 36; moderate: 8; severe: 1).
The patient with severe side effects had an allergic reac-
tion with diffuse rash. Patients’ median assessments of
the regimens according to a visual scale, were tolerability:
8 (range: 2–10); efficacy: 8 (range: 0–10). Of the 51 pa-
tients in Group B, 3 (5.9%) failed to take at least one pill
during treatment but only 2 (3.9%) were noncompliant;
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moderate: 2; severe: 1). The patient with severe side ef-
fects had intractable nausea, vomiting and diarrhea. Pa-
tients’ median assessments of treatment according to a
visual scale, were tolerability: 8 (range: 2–10) and effi-
cacy: 7 (range :2–9). No patient was lost to follow-up in
either group.
Microbiological studies
Endoscopies with biopsies and culture were successfully
and safely performed in all patients. H. pylori resistance
to CLARI was detected in 22 isolates (21.4%) in Group
A, and resistance to LVX in 13 (25.5%) isolates of Group
B. Only one case showed resistance to amoxicillin, with
a MIC level of 2 mg/L.
Twenty isolates of Group A had point mutations in
the 23S rRNA gene (A2143G/A2142G), and 9 isolates of
Group B in the gyrA gene. All isolates with mutations
had in vitro resistance to antibiotics related with those
genetic patterns. H. pylori cagA and vacA genotypes are
presented in Table 2.
Efficacy of eradication therapy
For Group A, the eradication rate was 68.9% (95% CI
59.4–77.1%) on ITT and 68.8% (95% CI: 58.9–77.2%) on
PP analysis. For Group B eradication rate was 52.9%
(95% CI: 39.5–66%) on ITT and 55.1% (95% CI: 41.3–
68.2%) on PP analysis.
Factors associated with eradication failure
We successfully treated 85.2% of patients with CLARI-
susceptible H. pylori, but only 9.1% of patients with
CLARI-resistant H. pylori (P <0.0001). None (0%) of the
Group B patients with LVX-resistant infections had suc-
cessful therapy, compared with 71.1% of patients with
LVX-susceptible infections (P <0.0001). Antibiotic resist-
ance was independently associated with treatment failure
in both groups (Table 3); however multivariate analysis
showed only history of frequent infections to indepen-
dently predict treatment failure in Group A (odds ratio
[OR]: 4.24; 95% CI: 1.04–17.24).
We then repeated the analysis excluding patients with
CLARI-resistant strains in Group A and LVX-resistantTable 2 H. pylori genotypes
Genotype Group A Group B
(n = 103) (n = 51)
cagA positive 44 (42.7%) 10 (19.6%)
vacA s1m1 24 (23.3%) 4 (7.8%)
vacA s1m2 28 (27.2%) 12 (23.5%)
vacA s2m1 1 (1%) 2 (3.9%)
vacA s2m2 50 (48.5%) 33 (64.7%)strains in Group B. In susceptible-only Group A, history
of frequent infections (OR: 4.76; 95% CI: 1.24–18.27)
and active tobacco consumption (OR: 5.25; 95% CI:
1.22–22.69) were associated with treatment failure. In
susceptible-only Group B, noncompliance was higher in
patients with treatment failure but not significantly so
(18.2% vs 0%; P = 0.078).
Discussion
Over the last two decades, widespread use of certain
antibiotics has progressively decreased H. pylori anti-
microbial susceptibility [20-22]. Resistance to CLARI
and fluoroquinolones develops rapidly and cannot be
overcome by increasing dose or duration of therapy [23].
The only way to identify effective drug combinations is
to regularly monitor the success of H. pylori eradication
and antibiotic resistance in every region.
Although PPI-CLARI-amoxicillin is probably the most
common anti-H. pylori treatment, its eradication rates
have decreased as resistance to antibiotics, particularly
macrolides, rises. Almost all consensus statements and
reviews still recommend it [2,4,20,24], although some
authors suggest longer therapy duration (10–14 days
instead of 7 days) or avoiding this regimen in regions
where H. pylori resistance to CLARI is higher than
15–20% [2,20].
Levofloxacin-based second-line therapies are an en-
couraging strategy for addressing eradication failures.
Multiple studies and meta-analyses show that combined
PPI, amoxicillin and LVX regimens have better results,
even in patients with more than one failed eradication
attempt and CLARI- and metronidazole-resistant strains
[10,12,25-27]. Unfortunately, fluoroquinolone resistance
is rapidly increasing in many countries [9,28].
The H. pylori prevalence rate in Portugal is > 80% [15].
Multiple drugs commonly used for this infection, such
as bismuth salts, tetracycline, furazolidone and rifabutin,
are not easily available in Portugal, and doxycycline
has disappointing results [17]. Although quadruple non-
bismuth, sequential and hybrid therapies have been pro-
posed as alternative first-line options, these treatments are
complex. Empiric triple-therapy with CLARI is still the
preferred first-line treatment and was recommended by
the Portuguese Society of Gastroenterology in 2008 [29],
with LVX-based treatment recently assuming a major
second-line or rescue position. Although by 2000, Cabrita
et al. reported H. pylori resistance to be 14.6% to CLARI
and 11.1% to ciprofloxacin among adults from the Lisbon
area [30], and a European multicenter study found resist-
ance rates in the same population of 20.7% for CLARI and
33.3% for metronidazole, the empiric triple treatment
remained the most common first-line regimen. In 2013,
Megraud et al. reported primary resistance as 31.5% to
CLARI and 26.3% to LVX in Portugal [9], and reportedly,
Table 3 Risk factors for eradication failure in univariate analysis











Female 27 (84.4%) 46 (64.8%) 0.043/2.94 (1.01–8.57) 19 (79.2%) 20 (74.1%) 0.749
Age 41.5 ± 13.7 41.7 ± 12.6 0.967 45.2 ± 10.4 45.3 ± 16.6 0.678
>50 years 9 (28.1%) 22 (31%) 0.820 9 (37.5%) 10 (37%) 1
Caucasian 30 (93.8%) 69 (97.2%) 0.586 23 (95.8%) 27 (100%) 0.471
No education or primary school 20 (62.5%) 53 (74.6%) 0.245 8 (33.3%) 11 (40.7%) 0.772
Urban residence 11 (34.4%) 37 (52.1%) 0.135 12 (50%) 9 (33.3%) 0.265
Non-ulcer dyspepsia 22 (68.8%) 41 (57.7%) 0.383 13 (54.2%) 21 (77.8%) 0.136
GERD/Chronic therapy with PPI 6 (18.8%) 18 (25.4%) 0.616 9 (37.5%) 8 (29.6%) 0.569
First-degree relatives with
gastric cancer
5 (15.6%) 9 (12.7%) 0.759 3 (12.5%) 4 (14.8%) 1
Iron-deficient anemia 6 (18.8%) 19 (26.8%) 0.462 4 (16.7%) 3 (11.1%) 0.693
Peptic ulcer 1 (3.1%) 8 (11.3%) 0.268 3 (12.5%) 1 (3.7%) 0.331
BMI 23.3 ± 3.3 25.2 ± 4.4 0.035 26.2 ± 4.4 23.9 ± 3.3 0.064
BMI < 26 kg/m2 29 (90.6%) 44 (62%) 0.004/5.92 (1.65–21.28) 13 (54.2%) 21 (77.8%) 0.136
Smoking 7 (21.9%) 6 (8.5%) 0.104 6 (25%) 5 (18.5%) 0.736
Alcohol consumption 4 (12.5%) 17 (23.9%) 0.290 3 (12.5%) 7 (25.9%) 0.300
Olive oil consumption ≥1 dl/week 18 (56.2%) 35 (49.3%) 0.531 11 (45.8%) 16 (59.3%) 0.406
History of frequent infections 11 (34.4%) 9 (12.7%) 0.015/3.61 (1.31–9.91) 7 (29.2%) 6 (22.2%) 0.749
Antibiotic consumption in the
last 12 months
12 (37.5%) 16 (22.5%) 0.151 19 (79.2%) 21 (77.8%) 1
Family history of gastric diseases 18 (56.2%) 31 (43.7%) 0.289 11 (45.8%) 18 (66.7%) 0.164
Adverse events 13 (40.6%) 32 (45.1%) 0.830 8 (33.3%) 8 (29.6%) 1
Incomplete treatment 6 (18.8%) 19 (26.8%) 0.462 3 (12.5%) 0 (0%) 0.097
No compliance 2 (6.2%) 5 (7%) 1 2 (8.3%) 0 (0%) 0.216
CagA negative 24 (75%) 35 (49.3%) 0.018/3.09 (1.22–7.81) 20 (83.3%) 21 (77.8%) 0.731
vacA s1m1 3 (9.4%) 21 (29.6%) 0.026/0.25 (0.07–0.90) 3 (12.5%) 1 (3.7%) 0.331
vacA s1m2 7 (21.9%) 21 (29.6%) 0,480 5 (20.8%) 7 (25.9%) 0.749
vacA s2m1 0 (0%) 1 (1.4%) 1 0 (0%) 2 (7.4%) 0.492
vacA s2m2 22 (68.8%) 28 (39.4%) 0.01/3.38 (1.39–8.20) 16 (66.7%) 17 (63%) 1
BMI: body mass index (kg/m2); GERD: gastroesophageal reflux disease.
Significant relationships (i.e., P <0.05) are shown in boldface type. Age is shown in years. Odds ratios are shown for significant variables only.
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Portugal have low eradication rates with CLARI- and
LVX-based ITT triple therapies [31]. However, the efficacy
of empiric H. pylori treatments in Portugal is little studied.
To our knowledge, this is the first study of the efficacy of
empiric triple regimens among patients in the central re-
gion of Portugal.
Our eradication rates were 68.9% for first-line ITT
treatment with 14-day PPI-CLARI-amoxicillin and 52.9%
for second-line/rescue treatment with 10-day PPI-LVX-
amoxicillin. These first-line results are slightly better than
the ones published by Cerqueira et al. for patients treated
in 2009–2010, and our second-line/rescue results are
similar [31].The main risk factor for treatment failure is undoubt-
edly antibiotic resistance [7]. We found 21.4% of H. pylori
isolates were for CLARI-resistant in Group A, and 25.5%
were LVX-resistant in Group B. Only two patients with
CLARI-resistant H. pylori, and none with LVX-resistant
H. pylori, achieved eradication. Strains of H. pylori in
Central Portugal are thus often resistant to CLARI and
LVX. Notably, although Group B excluded patients with
known histories of exposure to fluoroquinolones, its re-
sistance rate to LVX was very high, probably due to com-
mon use and misuse of macrolides and fluoroquinolones
for respiratory and urinary infections in Portugal and
the cross-resistance of H. pylori to all macrolides and
fluoroquinolones [9,32].
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more prevalent in the near future. A recent study of
children found a primary resistance rate to CLARI of
34.7% [33]. Clearly macrolides and fluoroquinolones
cannot be used to treat H. pylori in patients previously
exposed to them, as resistance is practically universal in
such circumstances [28].
Although we prescribed empiric treatments in patients
for whom H. pylori susceptibility patterns were deter-
mined, this study was a research protocol, the main ob-
jective of which was to establish the efficacy of commonly
used empiric treatments. Prescriptions were implemented
immediately after the endoscopies, but we received anti-
biotic susceptibility results much later, 2–3 weeks after
these procedures. Even among only those patients infected
by H. pylori strains with no resistance to CLARI in Group
A or LVX in Group B, eradication rates were 85.2% and
71.1%, respectively—well below the 90% accepted as the
minimum efficacy rate for H. pylori treatment regimens
[5]. As compliance and adverse event rates did not signifi-
cantly differ, these factors cannot be considered as respon-
sible for such failures. However, in Group B, treatment
failure tended to be higher in noncompliant patients,
although not significantly so, due to the limited number
of patients.
History of frequent infections was a risk factor for
eradication failure in all circumstances, even in patients
with no H. pylori resistance to CLARI. One possible
explanation is that our methodology underestimated
H. pylori resistance to macrolides. Infection by multiple
strains, with different resistance patterns, is common,
but subculture testing might mask identification of re-
sistant strains [34,35]. This is a potential cause of treat-
ment failure and negative cultures; thus direct molecular
studies of biopsy specimens might be more illuminating
[36]. For CLARI, De Francesco et al. recently reported
that the prevalence of usually identified point mutations
A2143G, A2142G and A2142C might be decreasing [37].
However, we identified mutations in positions A2143G/
A2142G of 23S rRNA gene in 20 of the 22 resistant
strains. Notably, the methodology we used does not dis-
tinguish A2143G from A2142G, but the clinical signifi-
cance of this limitation is controversial, although some
authors state that the A2143G mutation is the one that
significantly lowers H. pylori eradication rate [7]. Point
mutation A2142C was not detected and we did not
search for other mutations; this can be a limitation of
our work [37].
Active tobacco consumption was also a risk factor for
failure in patients with CLARI-susceptible H. pylori. This
negative effect is already known and may result from a
reduction of antibiotic delivery due to a decreased gas-
tric blood flow, lower intragastric pH or increased activ-
ity of the vacuolating toxin activity in gastric cells [2,38].We had only one case of H. pylori resistance to amoxi-
cillin, but that did not determine eradication failure. Re-
sistance to this antibiotic has also been held responsible
for treatment failure, but there is no accurate estimate of
its effect [39,40].
H. pylori genotype can be important as it is reported
to be strongly associated with eradication success, an-
tibiotic susceptibility and H. pylori virulence factors
[14,41,42]. Genotypes cagA negative and vacA s2m2
induce less inflammation and may contribute to re-
duced antibiotic delivery and decreased H. pylori era-
dication. Our univariate analysis also suggested this
association but logistic regression did not confirm it,
although the limited number of patients might have af-
fected these results.
Another possible explanation for our results is that
PPI and amoxicillin might have been prescribed in inad-
equate doses and/or intervals between administrations.
Generally, Caucasians metabolize PPI quickly and might
need higher doses and frequency of PPI administration
[43]. The same might be needed for amoxicillin, as its
bactericidal effect depends on % time above MIC and its
plasma half-life is very short; thus frequent dosing for
amoxicillin is necessary [44]. However, we prescribed the
combinations traditionally supported in the literature.
Different combinations, with four daily administrations
of PPI and amoxicillin, could eventually be tested in fu-
ture studies.
Various diseases can influence H. pylori eradication
rates. Patients with peptic ulcers tend to respond better
to treatment than patients with non-ulcer dyspepsia
[2,45,46]. Although our study found no association be-
tween disease manifestations and therapeutic failure,
relatively few patients with peptic ulcers were included.
The predominance of non-ulcer dyspepsia in our series
explains the high number of female patients, as non-
ulcer dyspepsia is more common in women [47].
Another limitation of our study was the relatively small
study cohort. First, we included only patients with previ-
ous positive UBT and indications for upper endoscopy,
with very restrictive exclusion criteria, which limited the
number of includible patients. Second, when our pro-
tocol was designed, no clear rules were in place on
interrupting treatment of patients in prospective studies
for H. pylori treatments. However, Maastricht III con-
sensus established that proposed therapies must achieve
eradication rates ≥80%. In following these recommen-
dations, we decided to perform preliminary analyses of
each 50 patients and to stop the study if eradication
rate was less than 80%. That threshold occurred in the
first analysis for Group B and in the second one for
Group A. Even stricter stopping rules were more re-
cently proposed by Graham (50 patients; eradication
rate <90%) [48].
Almeida et al. BMC Gastroenterology  (2015) 15:23 Page 7 of 8Finally, some recent studies suggest that 14-day LVX-
based triple therapy can provide a >90% H. pylori eradi-
cation rate, but a 10-day duration may be suboptimal
[49]. Although our LVX-treated patients in Group B re-
ceived a 10-day regimen, 7- and 10-day regimens with
LVX were acceptable when our protocol was designed;
we chose the longer one specifically to optimize results.
Another problem with LVX is lack of consensus about
dosage: 250 mg 2×/day, 500 mg 1×/day, or 500 mg 2×/
day. The 10-day 500 mg 2×/day dose reportedly has
higher eradication rates, but still <80% [50]. Other authors
still use a 10-day rescue regimen with PPI, amoxicillin 1 g
and LVX 250 mg, all 2×/day [51].Conclusions
Empiric triple-therapies with PPI-CLARI-amoxicillin
and PPI-LVX-amoxicillin are ineffective as first- and
second-line H. pylori regimens, respectively, in the cen-
tral region of Portugal and they are now unacceptable
as treatments. The main reason for treatment failure is
high H. pylori resistance to CLARI and LVX.
History of frequent infections and active tobacco con-
sumption contribute to unsuccessful treatments with
CLARI for H. pylori strains with no resistance to this
drug. In patients with these characteristics, another tai-
lored first-line treatment is preferable.
For first-line empiric treatment, we suggest empiric
concomitant or hybrid therapies for 14 days. However,
study of the efficacy of these treatments in our region
is urgently needed. In light of the scarcity of effective
H. pylori antimicrobials in our country, if these re-
gimens fail, it is our opinion that second-line treat-
ments must be prescribed according to susceptibility
testing.
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